DDInter1939 DDInter1763
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) downregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) upregulates {v} (Gene) WIF1
WIF1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) downregulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Vinorelbine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Vinorelbine (Compound) downregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Temsirolimus (Compound)
Vinorelbine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Temsirolimus (Compound)
Vinorelbine (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Temsirolimus (Compound)
Vinorelbine (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Temsirolimus (Compound)
Vinorelbine (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Vinorelbine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)